Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844223 | 1.00 | PDGFRB (1.00) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL30241126 | 1.00 | PDGFRB (1.00) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL843785 | 0.79 | PDGFRB (0.65) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL6200577 | 0.79 | PDGFRB (0.65) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL8499734 | 0.73 | NPC1 (0.71) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL6616540 | 0.73 | NPC1 (0.66) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL8500124 | 0.71 | NPC1 (0.68) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL31393433 | 0.70 | NPC1 (1.00) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL708998 | 0.70 | NPC1 (1.00) | PDGFRBFLT3KITNPC1RAB9A | |
| SCHEMBL6202965 | 0.70 | KDM4E (0.56) | PDGFRBFLT3KITNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| US-11712419-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11458199-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| EP-2887958-B1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | disclosed |
| US-10548841-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION | 2016-09-15 | — | — | US | disclosed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| EP-2342225-A1 | PROSTATE STEM CELLS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010048278-A1 | PROSTATE STEM CELLS AND USES THEREOF | GENENTECH, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-1228072-B1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2005-09-28 | — | — | EP | disclosed |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | LEVITZKI ALEXANDER (IL) | 2004-07-08 | — | — | US | disclosed |
| US-6673798-B2 | PLATELET DERIVED GROWTH FACTORS (PDGF); 1,2-DIMETHYL-6-(2-THIOPHENE)IMIDAZOLO(5,4-G)QUINOXALINE PREPARATIONS FOR EXAMPLE; USE TREATING PROLIFERATIVE MALIGNANT AND NON-MALIGNANT DISEASES; STENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-01-06 | — | — | US | disclosed |
| EP-1228072-A4 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2003-05-07 | — | — | EP | disclosed |
| EP-1228072-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2002-08-07 | — | — | EP | disclosed |
| US-6358954-B1 | IMIDAZO(4,5-G)QUINOXALINE DERIVATIVES; ANTITUMOR, ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-03-19 | — | — | US | disclosed |
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2002-03-07 | — | — | US | disclosed |
| WO-2001034607-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | PDGFRB 1/4885FLT3 12/4885KIT 49/4885 |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | VEGFA, PDGFA, PGF | PDGFRB 14/4885FLT3 2026/4885KIT 288/4885 |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | PDGFRB 1/4885FLT3 12/4885KIT 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.